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ARTICLE
Quantification of Adverse Drug Reactions Related to Drug 
Switches in The Netherlands
Pieter J. Glerum1,2,*, Marc Maliepaard1,3, Vincent de Valk4, Joep H.G. Scholl5, Florence P.A.M. van Hunsel5,  
Eugène P. van Puijenbroek5,6, David M. Burger7 and Kees Neef2
We performed a retrospective cohort study in the Dutch patient population to identify active substances with a relatively 
high number of adverse drug reactions (ADRs) potentially related to drug switching. For this, we analyzed drug switches and 
reported ADRs related to switching between June 1, 2009, and December 31, 2016, for a selection of 20 active substances. We 
also compared pharmacovigilance analyses based on the absolute, switch-corrected, and user-corrected numbers of ADRs. 
In total, 1,348 reported ADRs and over 23.8 million drug switches were obtained from the National Health Care Institute in 
The Netherlands and from Lareb, which is The Netherlands Pharmacovigilance Centre. There was no correlation between the 
number of ADRs and the number of switches, but, on average, we found 5.7 reported ADRs per 100,000 switches. The number 
was relatively high for rivastigmine, levothyroxine, methylphenidate, and salbutamol, with 74.9, 50.9, 47.6, and 26.1 ADRs per 
100,000 switches, respectively. When comparing analyses using the absolute number and the switch-corrected number of 
ADRs, we demonstrate that different active substances would be identified as having a relatively high number of ADRs, and 
different time periods of increased numbers of ADRs would be observed. We also demonstrate similar results when using 
the user-corrected number of ADRs instead of the switch-corrected number of ADRs, allowing for a more feasible approach 
in pharmacovigilance practice. This study demonstrates that pharmacovigilance analyses of switch-related ADRs leads to 
different results when the number of reported ADRs is corrected for the actual number of drug switches.
Generic drugs are highly similar to their brand-name 
counterparts. Generic drugs comprise identical active sub-
stance(s), have the same pharmaceutical form, and have 
been shown to be bioequivalent to the brand-name drug. 
Limits for bioequivalence are set to achieve similar clin-
ical safety and efficacy, and if bioequivalence has been 
demonstrated, then branded and generic drugs are consid-
ered therapeutically equivalent.1 From a pharmacological 
perspective, it is, therefore, unexpected that a different 
clinical profile is observed for a generic drug as com-
pared with a brand-name drug, and that an adverse drug 
reaction (ADR) is experienced following a switch between 
bioequivalent drug products. However, cases of ADRs fol-
lowing drug switches are published;2–4 some studies on 
switching demonstrate increased health care utilization,5 
and patients’ and prescribers’ perceptions of generics, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  The number of drug switches is currently not accounted 
for in the analysis of adverse drug reactions (ADRs) pos-
sibly resulting from those switches.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  What are the relative number of reported ADRs per 
number of switches for the 20 active substances in our 
study and are those numbers different for ADR numbers 
not corrected for the number of switches?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  We now have a tool at hand that increased the likeli-
hood of identifying relevant switch-related ADR peaks and 
the use of switch-corrected ADR data in routine pharma-
covigilance analyses seems to be advisable.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
✔  This systematic study of the perceived problems of 
drug switching can aid in further (pharmacovigilance) re-
search and the discussion on the acceptability of drug 
switching and generic interchangeability.
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and generic switches are not always positive.6–10 A need 
exists to systematically study the perceived problems and 
possibly elucidate points for improvement on the phar-
macological and psychological assumptions of generic 
interchangeability.
Lareb, The  Netherlands Pharmacovigilance Centre, 
is responsible for pharmacovigilance signal detection in 
The Netherlands and regularly receives ADR reports related 
to generic switching. In 2017, Lareb published a report on 
these ADRs for active substances with at least 25 reported 
switch-related ADRs over a period of 10  years.11 Based 
on observed patterns for the absolute number of reported 
ADRs and a clinical review of each case, Lareb identified 
problems following switching: dysregulation of patients 
after switches of the thyroid hormone levothyroxine; break-
through bleeding on oral contraceptives with ethinylestradiol 
and levonorgestrel; reduced efficacy with inhalation drugs 
for the treatment of asthma; salbutamol and fluticasone/
salmeterol, skin reactions and curling of patches with ri-
vastigmine; injection site pain and injection site reactions 
with methotrexate; and reduced efficacy with anti-epileptics.
However, as acknowledged by the authors, and as is often 
the case for pharmacovigilance research, studying the ab-
solute numbers of ADRs is a classic example of a “floating 
numerator”; that is, the number of cases is not related to the 
size of the population at risk. The relative risk may be low for 
drugs that are often switched, but could be high for drugs that 
are switched less often. Furthermore, we expect that there 
is a background rate of reported ADRs per number of drug 
switches. The background rate is difficult to discern without 
knowledge of the number of drug switches, specifically be-
cause we know from previous work that the number of switches 
fluctuates on a monthly basis (P.J. Glerum, M. Maliepaard, 
V. de Valk, D.M. Burger, C. Neef, unpublished data).
The primary aim of the current investigation is to calcu-
late the relative number of reported ADRs per number of drug 
switches for the 20 active substances that were described in 
the Lareb report, in the time period between June 1, 2009, 
and December 31, 2016. (Temporary) increased numbers of 
reported ADRs (“peaks”) above the background level are of 
particular interest, as these could indicate a true increased in-
cidence of clinical discomfort following a drug switch. Further 
investigation of such a relative peak should then be performed 
to determine whether a causal association between a specific 
drug switch and the experienced ADRs can be deduced.
In addition, we examine whether different peaks would 
be observed using the absolute number of ADRs or using 
the switch-corrected number of ADRs. We also explore 
the feasibility of using the number of users, instead of drug 
switches, for correcting the absolute number of reported 
ADRs, because these data are more readily available.
METHODS
This is a retrospective cohort study of a selection of 20 
active substances in the Dutch patient population, with 
qualitative and quantitative descriptive analyses. We related 
the number of reported ADRs obtained from the database 
of the Lareb to the drug switches from the National Health 
Care Institute (ZIN).
Active substance selection was based on a Lareb report 
from 2017, in which drug switch-related ADRs were described 
for active substances with >  25 ADRs in a 10-year period 
from 2006. The following active substances (20) are included: 
atorvastatin, enalapril, esomeprazole, ethinylestradiol/levo-
norgestrel, irbesartan, levothyroxine, losartan, metformin, 
methotrexate, methylphenidate, metoprolol, omeprazole, 
pantoprazole, paroxetine, perindopril, rivastigmine, salbu-
tamol, salmeterol/fluticasone, simvastatin, and venlafaxine.
Patient switch data
We previously performed an extensive analysis of the drug 
switch data for the 20 drugs (P.J.  Glerum, unpublished 
data). A switch is defined as the replacement of a patient’s 
prescribed drug with a similar drug dispensed within the 
preceding 150 days, for the same active substance, same 
strength, and same route of administration, but with the 
drug product coming from a different manufacturer. The 
drug products before and after the switch could be both 
generic or brand-name drugs. In the ZIN data, analysis of 
consecutive dispenses is feasible from January 1, 2009, 
onward, thus we have reliable drug switch data from June 
1, 2009, until December 31, 2016. Furthermore, we col-
lected data on the total number of users of the 20 active 
substances from the same data source.
Reported ADR data
We obtained all spontaneously reported ADRs received 
by Lareb over the years 2009–2016, submitted by patients 
and healthcare professionals, both directly to Lareb and via 
marketing authorization holders. Only ADR reports that, ac-
cording to the reporter, were highly related to drug switching 
or drug substitution were included. For this purpose, re-
ports categorized under a specific subset of the Medical 
Dictionary for Regulatory Activities (MedDRA) Lowest-Level 
Terms (LLTs) were included (Table S1). For each reported 
ADR, we obtained the unique anonymized identification 
number, date of onset of the ADR, report-received date, 
MedDRA LLT, Anatomical Therapeutic Chemical (ATC) 
classification system code before switch, ATC code after 
switch, and sex and age of the patient.
The date of onset of the ADR was deemed most relevant 
to our study; however, this was not registered in 12.9% 
(375/2,901) of the reports. In these cases, the report- 
received date was used, minus the median difference be-
tween the receive date and the date of onset of all reported 
ADRs (53 days). We excluded 5.3% (155/2,901) of the reports, 
whose date of onset of the ADR was not between June 1, 
2009, and December 31, 2016. Furthermore, the interest 
of our study was drug switching between two products of 
the same active substance. We, therefore, excluded 5.2% 
(144/2,746) of the ADRs in which the registered ATC code 
before and after switch did not match. The final number of 
suitable ADRs was 2,602. We did not exclude reports in 
which the ATC code before the switch was not registered, 
which was the case in 33.7% (878/2,602) of the reports.
Data analysis
Aggregated data were exported from ZIN and Lareb data-
bases as a Microsoft Excel workbook and imported into R 
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software (version 3.5.1) using the package “xlsx.” Qualitative 
and quantitative descriptive analyses and data visualization 
were performed using base R and R Studio.
Descriptive analyses of reported ADR data were per-
formed and presented per anatomic subgroup of the ATC 
classification system and for each of the 20 selected drugs. 
Both the patient switch data and the ADR data were aggre-
gated on a quarterly (3-month) basis, as this is a common 
time frame for analyses in pharmacovigilance. In the ab-
sence of switch data, ADR data before July 2009 were not 
included in the quarterly analyses.
The numbers of reported ADRs per number of switches 
were calculated by dividing the quarterly number of ADRs for 
each active substance by the quarterly number of switches 
for that active substance. Analogously, numbers of reported 
ADRs per number of users were calculated by dividing the 
quarterly number of ADRs by the number of users.
In this study, we define a peak in the number of ADRs as 
the value exceeding a threshold. This threshold was sub-
jectively defined as the mean value of the number of ADRs 
in all quarters for all included active substances, plus one 
times its SD.
RESULTS
Number of reported ADRs
Our analyses included a total of 2,602 reported ADRs related 
to drug switching during the study period June 1, 2009, until 
December 31, 2016. Of the included ADRs, 63.9% were re-
ported for female patients, and the mean age of the patients 
was 53.1 years (range 0–95 years). In Table S2 an overview 
is presented of the number of ADRs per ATC anatomic main 
group. Differences between anatomic groups are observed, 
with, for example, a large number of reported ADRs for the 
nervous system subgroup (n = 595) and a small number for 
dermatological drugs (n  =  13). However, as the number of 
switches per active substance is unknown, no inferences can 
be made with regard to the relative risk per anatomic group.
In Figure 1 the data are illustrated graphically, with each 
shaded band indicating one specific active substance. 
From this figure, large differences can be observed regard-
ing the relative contribution of active substances within 
each anatomic group, for example, a major contribution of 
levothyroxine in the subgroup “systemic hormonal prepa-
rations” (H) (95% (360/379) of the total number of switches 
in the ATC group) and of omeprazole (41.3% (124/300)) 
in the “alimentary tract and metabolism” subgroup (A). 
The 20 active substances included in our further analy-
ses represent 51.8% (1,348/2,602) of all reported ADRs 
in our data set; they are marked in Figure 1. Table 1 pro-
vides an overview of both the number of reported ADRs 
and the number of drug switches of the included active 
substances.
Relative number of reported ADRs
To examine the relation between the number of reported 
ADRs and the number of drug switches, the quarterly number 
of ADRs and quarterly number of switches for the 20 selected 
active substances are depicted in Figure 2. The mean num-
ber at which ADRs are reported for all active substances in 
our selection is 5.7 per 100,000 switches. However, no linear 
correlation between the number of ADRs and the number of 
switches was identified, and a high variability in the number of 
ADRs reported per quarter is observed.
In Figure 3, the mean quarterly reported number of ADRs 
and mean quarterly number of switch-corrected ADRs are 
compared for all 20 active substances in the data set. Figure 3 
illustrates that there is a cluster of active substances with a 
similar, relatively low quarterly number of ADRs per 100,000 
switches. In contrast, the following four active substances 
demonstrate notably higher numbers: rivastigmine (74.9 ± 188 
per 100,000 switches, mean ± SD), levothyroxine (50.9 ± 64.2), 
methylphenidate (47.6 ± 37.1), and salbutamol (26.1 ± 45.2). 
The mean relative risk of reporting an ADR following a rivastig-
mine switch in our study period, therefore, seems 65-fold 
higher, compared with a simvastatin product switch (i.e., 74.9 
vs. 1.15 reported ADRs per 100,000 switches).
Comparison between relative number and absolute 
number of reported ADRs
Figure 3a,c depict the ranking of the active substances 
based on both mean number and switch-corrected num-
ber of ADRs. The ranking order of these two measures 
does not fully overlap. More specifically, for rivastig-
mine, for example, the mean absolute number of ADRs 
(1.27 ± 3.07) is relatively low, whereas the mean number 
of switch-corrected ADRs is relatively high (74.9 ± 188 per 
100,000 switches). For omeprazole, it is the opposite: a 
relatively high mean number of ADRs (4.07  ±  9.41) and 
a relatively low mean number of switch-corrected ADRs 
Figure 1 Overview of all spontaneously reported adverse 
drug reactions (ADRs) related to drug switching, for all 
active substances, from June 2009 to December 2016 in The   
Netherlands, as obtained from Lareb. Each bar is a sum of 
all reports in a specific anatomic group. Each individual color 
represents the total number of reported ADRs for one specific 
Anatomical Therapeutic Chemical code. Colored and striped 
parts indicate the 20 products selected for further study.
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(3.28 ± 4.97 per 100,000 switches) exist. For levothyrox-
ine, salbutamol, and methylphenidate, both the absolute 
number and switch-corrected number of ADRs are rela-
tively high.
Large SDs on the mean values are observed. This 
indicates that large differences can be observed between dif-
ferent quarters. Studying mean values ignores the fluctuation 
in the data, which are essential in the (real-time) detection 
of temporal increases. Figure 4 presents an example of the 
study over time for the number of reported ADRs (absolute 
and switch-corrected) related to esomeprazole. The largest 
absolute number of ADRs was observed in the first quarter 
of 2011 (six reported ADRs), and it coincides with the larg-
est number of quarterly switches (83,254). As a result, the 
number of switch-corrected ADRs in the first quarter of 2011 
(7.21 per 100,000 switches) is lower than the number of 
switch-corrected ADRs observed in the last quarter of both 
2010 and 2012, the second quarter of 2015, and the first 
quarter of 2016 (with 8.68, 12.0, 11.96, and 12.65 reported 
ADRs per 100,000 switches, respectively), all representing 
quarters for which a lower absolute number of ADRs were 
reported (i.e., 2 or 3). This exemplifies that, when corrected 
for the number of switches, a peak in the absolute number of 
ADRs does not necessarily translate into the most relevant 
peak in ADRs. Similarly, a lower absolute number of ADRs 
could be more relevant if the number of switches in a quarter 
is relatively low.
To further examine the question as to whether differ-
ent peaks would be observed using the absolute number 
of ADRs vs. the switch-corrected number of ADRs, the 
absolute number of quarterly ADRs was plotted against 
the switch-corrected number of ADRs for all 20 included 
active substances (Figure 5a). This allows for a visual as-
sessment of the difference between the two methods of 
“peak detection.” The figure illustrates a number of data 
Table 1 Overview of each specific active substance included in the analysis, including INN, European brand name, total number of reported 
ADRs related to drug­switching, and total number of switches for these active substances, for the period June 2009 to December 2016 in The 
Netherlands
INN EU brand name Total number of reported ADRs Total number of switches
Levothyroxine Thyrax Duotab 360 507,396
Salbutamol Ventolin 133 493,270
Methylphenidate Ritalin 129 223,496
Omeprazole Losec 124 2,742,659
Ethinylestradiol/levonorgestrel Microgynon 68 483,996
Atorvastatin Lipitor 61 2,007,886
Metoprolol Lopresor 53 2,723,408
Simvastatin Zocor 49 4,241,382
Salmeterol/fluticasone Seretide 43 793,693
Irbesartan Aprovel 40 446,312
Paroxetine Seroxat 38 853,542
Rivastigmine Exelon 38 30,722
Pantoprazole Pantozol 36 2,192,881
Metformin Glucophage 34 1,915,225
Esomeprazole Nexium 28 716,320
Losartan Cozaar 28 902,258
Venlafaxine Efexor 26 422,532
Enalapril Renitec 22 776,436
Perindopril Coversyl 22 1,222,092
Methotrexate Metoject 16 161,603
Total   1,348 23,857,109
ADRs, adverse drug reactions; INN, international nonproprietary name.
Figure 2 Plot of the absolute number of reported adverse 
drug reactions (ADRs) related to drug switching and number of 
switches in The Netherlands for all included active substances 
(n = 20) in the data set. Each data point is the number of reported 
ADRs and number of switches for one specific quarter year.
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points clustered at the lower values of both axes and a 
number of data points deviating from that cluster. To inter-
pret the results, we arbitrarily defined a threshold above 
which a data point is considered to be a peak or a part 
thereof.
Data are available for 30 quarter years for each individ-
ual active substance, amounting to 600 quarters. On the 
one hand, based on the absolute number of ADRs, 4.3% 
(26/600) of the quarters would be identified as a peak. On 
the other hand, based on the switch-corrected ADRs, 5.7% 
(34/600) of the quarters would be identified as a peak. 
Furthermore, 2.5% (15/600) of the quarters would be identi-
fied by both methods, and 1.8% (11/600) of the peaks that 
were identified based on the absolute number of ADRs was 
not identified by the switch-corrected ADR method. The 
latter 1.8% could be characterized as false positives of the 
absolute ADR method, or a “type 1” error, as these peaks 
would erroneously be identified as peaks when, in fact, they 
are explained by an increased number of switches. Similarly, 
3.2% (19/600) of the ADR peaks would only be identified 
with the switch-corrected ADR method and not by the ab-
solute number of ADRs method. These could be defined as 
“type 2” errors or false negatives of the absolute number of 
ADRs method.
In Figure 5a, the reported ADR peaks for the following five 
active substances visually stand out: rivastigmine, methyl-
phenidate, levothyroxine, omeprazole, and salbutamol. For 
rivastigmine, a large switch-corrected ADR peak is observed 
for 7 of 30 quarters, but only 1 of these 7 quarters (14.3%) 
is above the threshold for the absolute number of ADRs. 
Figure 3 Comparison between mean number of quarterly reported adverse drug reactions (ADRs) and mean switch-corrected 
number of quarterly ADRs, with bar chart (a) of mean switch-corrected number of quarterly reported ADRs related to drug switching 
per 100,000 switches; plot (b) of each active substance, with the mean absolute number of quarterly reported ADRs on the x-axis 
and the mean of switch-corrected number of quarterly reported ADRs per 100,000 switches on the y-axis; and bar chart (c) of mean 
absolute number of quarterly reported ADRs, error bars indicate quarterly SD.
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Likewise, for methylphenidate, 26.7% (8/30) of the quarters is 
above the switch-corrected ADR threshold but not above the 
threshold for the absolute number of ADRs. These data indi-
cate false negatives in the absolute number of ADRs method.
For levothyroxine, 9 of 30 quarters are above the 
threshold for the absolute number of ADRs, of which 
55.6% (5/9) is not identified by the switch-corrected ADR 
method, thus indicating false positives in the absolute 
number of ADRs method. Likewise, for omeprazole, 10% 
(3/30) of the quarters is above the threshold for the abso-
lute number of ADRs; however, none of these three were 
identified by the switch-corrected ADR method, again in-
dicating false positives for the absolute number of ADRs 
method. For salbutamol, no false positives or negatives 
are identified, as the same five quarters are identified by 
both methods.
Figure 4 Number of quarterly switches (black line), absolute number of reported adverse drug reactions (ADRs; gray bar plot) and 
quarterly number of switch-corrected reported ADRs (per 100,000 switches, color bar plot) for esomeprazole in The Netherlands.
Figure 5 (a) Comparison between switch-corrected, and user-corrected quarterly reported adverse drug reactions (ADRs), with a plot 
(a) of the absolute number of quarterly reported ADRs per active substance on the x-axis and number of switch-corrected quarterly 
reported ADRs per 100,000 switches on the y-axis; and a plot of (b) of absolute number of quarterly reported ADRs per active 
substance on the x-axis and number of user-corrected quarterly reported ADRs per 100,000 users on the y-axis; gray lines connect 
values for quarters of a single active substance in chronological order, and dashed lines are the threshold values, defined as the mean 
number of the absolute, switch-corrected, or user-corrected reported ADRs + 1 SD. The total number of quarterly data points per 
active substance is 30.
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User­adjusted analysis
Data on the absolute number of drug switches are only 
available in The Netherlands in retrospect. This may hin-
der the use of the number of switches during real-time 
pharmacovigilance analyses. A more practical approach 
to put the number of ADRs into perspective would, there-
fore, be to use the number of users instead of the number 
of switches.
The absolute number of quarterly ADRs and the user- 
corrected number of quarterly ADRs are depicted in Figure 5b. 
Comparing Figure 5a,b, similar trends are observed for the 
values of rivastigmine, levothyroxine, methylphenidate, and 
omeprazole. Table 2 provides a detailed comparison of the 
number of ADRs above and below the threshold using either 
switch-corrected or user-corrected ADRs, as compared with 
the outcome for the absolute number of ADRs method, and 
it shows a similar trend using both methods.
Although numerical differences can be observed with re-
spect to the number of false positives and false negatives 
between both methods, the overall impression is that both 
methods result in similar findings regarding the number of 
active substances with identified peaks and the percent-
age of quarters with values above or below the threshold. 
Similarity in the outcome of the switch-corrected and 
user-corrected ADR methods depends on the correlation 
between the quarterly number of users and the quarterly 
number of switches. Figure S1 is a depiction of the cor-
relation and there is a linear correlation (R2 = 0.72) with a 
significant slope (P = 2.48*10−6). On average, ~ 91 quarterly 
switches per 1,000 users are observed for the 20 active sub-
stances included in our analysis.
DISCUSSION
Pharmacovigilance is a useful tool in the identification of 
clinical consequences of (generic) drug switching. Given 
the importance for each individual patient, every reported 
ADR should always undergo thorough causal and clinical 
review.
We combined the number of drug switches and the num-
ber of related ADRs for a period of 7.5 years between June 1, 
2009, and December 31, 2016. We demonstrated that, in this 
period, rivastigmine, levothyroxine, methylphenidate, and 
salbutamol have a relatively high number of switch-related 
ADRs. Without switching data, the potential exists to draw 
false positive (noted, e.g., for omeprazole) or false negative 
(noted, e.g., for rivastigmine) conclusions. We also revealed 
that, without switching data, different active substances in 
our selection of 20 would be identified as having a high prev-
alence of switch-related ADRs. The use of switch-corrected 
ADR data should be considered in pharmacovigilance analy-
ses to avoid misinterpretation of switch-related ADR signals.
This is the first systematic, nationwide analysis of clinical 
discomfort from drug switches, using reported ADRs and 
the specific population at risk. Others have used indirect 
measures of discomfort, such as switchback rates.12 In a 
study on temporal trends in ADR reporting before and after 
generic introduction, the peak reporting numbers for five 
anti-epileptic active substances were calculated as being in 
the range of 50–450 per 100,000 dispensed prescriptions.13 
In that study, ADRs were not selected on specific LLTs and 
are expressed by number of prescriptions, which makes it 
difficult to compare with our study. In a recent analysis of 
a large switch in France between two levothyroxine drug 
products, an ADR reporting rate of 1.44% is mentioned.14 
This is based on an estimated 2.1 million patients switching 
and 31,411 reported ADRs over a period of 13 months. The 
relative number of 1,440 of 100,000 switches in 13 months 
is higher than in our study, as we found a peak of 220 ADRs 
per 100,000 switches in 3 months for levothyroxine. The au-
thors postulate a causal relation between the high number 
of reported ADRs and the proportion of subjects outside 
the bioequivalence limits, as found in a pharmacokinetic 
study. This relation is heavily debated.15–18 In a similar sit-
uation for levothyroxine in 2007 and 2008 in New Zealand, 
the increased number of reported ADRs was attributed to 
other factors, such as inaccurate information and media at-
tention.19 Others have postulated an analytical framework 
that is comparable to our approach, and this confirms the 
potential of combining spontaneously reported ADRs and 
health care claims data for the detection of generic issues.20
In our data set, we did not identify a correlation between 
the quarterly number of drug switches and the quarterly 
number of reported ADRs using data for all 20 active sub-
stances. This finding suggests that the increased number 
of ADRs is not merely a result of an increased number of 
switches. Thus, in many cases, the rate of reported ADRs in-
deed does change (temporarily), which may be an indication 
of an issue related to drug switches for those active sub-
stances. The reason for an increased rate of reported ADRs 
can be either an increase in the number of occasions on 
which a patient experiences a clinical consequence of a drug 
switch or a larger portion of the patients reporting their ex-
perienced ADRs. Furthermore, the absence of a correlation 
Table 2 Comparison between percentages of quarters above or below the threshold of either the switch­corrected or user­corrected reported 
ADR methods for the 20 selected active substances in this study
 
Absolute number of reported ADRs below threshold Absolute number of reported ADRs above threshold
Switch adjusted User adjusted Switch adjusted User adjusted
Reported ADR number above 
threshold
3.17% (19/600) 1.50% (9/600) 2.50% (15/600) 1% (6/600)
Reported ADR number below 
threshold
92.5% (555/600) 94.2% (565/600) 1.83% (11/600) 3.33% (20/600)
ADRs, adverse drug reactions.
False negatives are marked in light gray, and false positives are marked dark gray.
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between the number of switches and the number of ARDs 
questions the idea that the same general “background ADR 
reporting rate” is present for all active substances for which 
ADRs related to drug switches are reported.
Further in our study, we demonstrated that correcting 
the number of ADRs by number of users, instead of number 
of switches, is a suitable alternative, because a compa-
rable number of ADR peaks over time were identified by 
both methods. This is not an unexpected finding, as the 
number of switches is related to the number of users (see 
Figure S1). The number of users is, however, a mean value, 
and unlike the number of switches in The Netherlands, it 
does not demonstrate changes over a short period of time. 
Therefore, the user-corrected ADR method cannot put into 
perspective the temporal increases in reported ADR peaks. 
This is not of great influence on our analysis, presumably 
because there is no strong correlation between peaks in 
the number of ADRs and peaks in the number of switches.
On average, in our data set of 20 active substances in The 
Netherlands, we found 364 switches per 1,000 users per 
year. In a study on the frequency of switching and adherence 
of inhalation medication, a yearly percentage switch of ~ 5% 
of total users was identified.21 This is low compared with our 
results, perhaps because multiple switches per patient and 
switches between generics were not accounted for in that 
publication. We are unaware of other literature references on 
drug switch frequencies.
Study limitations
This study is based on data from spontaneous ADR re-
porting, which is known to be subject to under-reporting, 
varying by type of active substance and type of ADR.22 
This limits the generalizability of our study, as we are 
not able to calculate an absolute risk of ADRs following 
drug switches, only a relative number of reported ADRs. 
Moreover, changes in the number of reported ADRs over 
time could simply be changes in the reporting rate and 
not true changes in the number of experienced ADRs. 
However, we believe that spontaneous reports are the 
most objective and systematically acquired data avail-
able to study clinical discomfort regarding drug switches. 
Furthermore, conclusions on the calculated number of 
reported ADRs can still be drawn relative to other active 
substances in the data set.
We present data for 20 active substances only. 
Nevertheless, these 20 active substances have the largest 
number of reported ADRs in The Netherlands and, therefore, 
provide an adequate number of ADRs on which to base cal-
culations. As in our previous study (P.J. Glerum, unpublished 
data), we believe these 20 active substances represent a 
valuable sample, because active substances are included 
with both high and low numbers of switches, as well as high 
and low numbers of users. The active substance selection 
includes not only 5 of the 10 most prescribed active sub-
stances in The Netherlands in 2016 (between 688,000 and 1 
million users), but also data for rivastigmine, which has, on 
average, only 15,000 users.
In theory, a more detailed level of analysis is possible using 
the Lareb and ZIN data sources, for instance, analysis of 
manufacturer-specific switches or analysis of ADRs reported 
for a specific patient subgroup. Although interesting, more 
detailed analyses are limited because of the smaller num-
ber of ADRs that can be included in them. In addition, the 
data obtained for our study did not support manufacturer- 
specific analysis, as this information was not registered by 
Lareb in the first part of the study period. Furthermore, sub-
group analyses could not be performed, as the ZIN data were 
aggregated, and patient characteristics were not included.
We used all reported ADRs for which a certain LLT was 
registered. This limits the study, as allocation of LLTs to ADR 
reports is a subjective action. “Substitution” is particularly 
ambiguous terminology, as various interpretations are of-
fered in literature. However, we gathered all ADRs from the 
same pharmacovigilance center and are, therefore, con-
fident that the terminology and interpretation is consistent 
and similar within our study data.
The threshold for peak identification was arbitrarily chosen 
as the mean plus one SD. This is a common approach when 
analyzing data, such as those in this study; however, it is only 
a mathematical approach to peak identification. Conclusions 
drawn from these data can, therefore, differ if different threshold 
values are chosen, and the best threshold for actual pharma-
covigilance analyses may be a subject for further research.
Future directions
In this study, we demonstrate the importance of incor-
porating the number of drug switches when analyzing 
switch-related ADRs. Although we consider each reported 
ADR to be important, and we know that ADRs can have a 
significant impact on quality of life on an individual level,23 
we believe that an ADR is less informative in analyzing the 
clinical discomfort of drug switching when a large number 
of switches underlies that specific ADR.
Our recommendation is to incorporate the number of drug 
switches in drug switch-related ADR pharmacovigilance 
analyses, when feasible. If not, it would at least be desirable 
to incorporate the number of users, which is a reasonable al-
ternative to the number of switches. Alternatively, it may be 
interesting to use an estimated number of drug switches by 
simulating the number of drug switches, based on the num-
ber of users, seasonality (known to occur in The Netherlands), 
and other factors that are unknown at this point. Further vali-
dation of either methodology is recommended.
CONCLUSION
We demonstrate that adjusting the absolute number of 
reported ADRs for the number of drug switches leads to 
identification of different ADR peaks between June 1, 2009, 
and December 31, 2016, at least in our selection of 20 ac-
tive substances with a relatively large number of ADRs 
in The Netherlands. By using the switch-corrected number 
of ADRs in pharmacovigilance analyses, the likelihood of 
identifying relevant switch-related ADR peaks may be in-
creased. Therefore, the use of switch-corrected ADR data in 
routine pharmacovigilance analyses seems to be advisable. 
Although the number of switches is theoretically the best 
measure to put the reported ADRs related to drug switching 
in perspective, in the absence of such data, the mean num-
ber of users could be a useful alternative measure.
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